AbbVie - 11 Year Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2013 adjusted for splits and dividends. The latest closing stock price for AbbVie as of July 19, 2024 is 172.32.
  • The all-time high AbbVie stock closing price was 178.73 on March 28, 2024.
  • The AbbVie 52-week high stock price is 182.89, which is 6.1% above the current share price.
  • The AbbVie 52-week low stock price is 135.85, which is 21.2% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 159.33.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 166.5554 155.3780 178.7285 153.3752 172.3200 14.37%
2023 141.5584 151.7254 156.9934 126.1564 150.6628 -0.23%
2022 136.8492 121.7575 158.9695 119.9177 151.0059 24.04%
2021 99.8293 90.4545 122.2160 88.8080 121.7395 32.40%
2020 76.4289 72.8753 93.2519 53.1920 91.9476 27.61%
2019 61.9795 68.7123 73.4450 50.5187 72.0534 1.50%
2018 73.7659 72.9547 91.9931 59.9491 70.9917 -0.98%
2017 55.0861 44.6228 72.8065 43.3488 71.6945 60.13%
2016 42.7612 39.6268 47.7390 35.5960 44.7730 9.88%
2015 42.1369 43.8624 48.5351 33.2023 40.7480 -6.46%
2014 36.4885 33.5055 46.4053 30.4282 43.5628 27.97%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $304.294B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Novartis AG (NVS) Switzerland $216.930B 15.08
Pfizer (PFE) United States $169.828B 21.11
Sanofi (SNY) $128.207B 12.08
Innoviva (INVA) United States $1.073B 7.54